A randomised controlled trial to assess the efficacy of Laparoscopic Uterosacral Nerve Ablation (LUNA) in the treatment of chronic pelvic pain: The trial protocol [ISRCTN41196151] by 
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Women's Health
Open Access Study protocol
A randomised controlled trial to assess the efficacy of Laparoscopic 
Uterosacral Nerve Ablation (LUNA) in the treatment of chronic 
pelvic pain: The trial protocol [ISRCTN41196151]
The LUNA Trial Collaboration*
Address: Department of Obstetrics and Gynaecology, Birmingham Clinical Trials Unit and Department of Public Health and Epidemiology, 
University of Birmingham B15 2TT, UK
Email: The LUNA Trial Collaboration* - pallavi.latthe@bwhct.nhs.uk
* Corresponding author    
Abstract
Background: Chronic pelvic pain is a common condition with a major impact on health-related
quality of life, work productivity and health care utilisation. The cause of the pain is not always
obvious as no pathology is seen in 40–60% of the cases. In the absence of pathology there is no
established treatment. The Lee-Frankenhauser sensory nerve plexuses and parasympathetic ganglia
in the uterosacral ligaments carry pain from the uterus, cervix and other pelvic structures.
Interruption of these nerve trunks by laparoscopic uterosacral nerve ablation (LUNA) may alleviate
pain. However, the balance of benefits and risks of this intervention have not been reliably assessed.
LUNA has, nevertheless, been introduced into practice, although there remains controversy
regarding indications for LUNA. Hence, there is an urgent need for a randomised controlled trial
to confirm, or refute, any worthwhile effectiveness. The principal hypothesis is that, in women with
chronic pelvic pain in whom diagnostic laparoscopy reveals either no pathology or mild
endometriosis (AFS score ≤ 5) LUNA alleviates pain and improves life quality at 12 months.
Methods/Design: The principal objective is to test the hypothesis that in women with chronic
pelvic pain in whom diagnostic laparoscopy reveals either no pathology or mild endometriosis (AFS
score ≤ 5) LUNA alleviates pain and improves life quality at 12 months. A multi-centre, prospective,
randomised-controlled-trial will be carried out with blind assessment of outcomes in eligible
consenting patients randomised at diagnostic laparoscopy to LUNA (experimental group) or to no
pelvic denervation (control group). Postal questionnaires including visual analogue scale for pain
(primary outcome), an index of sexual satisfaction and the EuroQoL 5D-EQ instrument (secondary
outcomes) will be administered at 3, 6 and 12 months. The primary assessment of the effectiveness
of LUNA will be from comparison of outcomes at the one-year follow-up, although the medium-
term and longer-term risks and benefits of LUNA will also be evaluated.
The sample size for this trial has been estimated as 420 patients in total using the hypothesis that 
LUNA will alleviate pain symptoms (i.e. reduce pain scores on a VAS) more than no intervention 
at one-year following diagnostic laparoscopy and taking into consideration 20% loss to follow-up. 
The intention to treat analysis to address the principal research questions will be conducted using 
the one-year follow-up data.
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Background
Pelvic pain remains the single most common indication
for referral to a Gynaecology clinic accounting for 20% of
all outpatient appointments [1,2]. Five percent of all new
appointments are for chronic pelvic pain[3]. It continues
to be one of the most difficult and perplexing problems
encountered in Gynaecology. Pelvic pain has a major
impact on health-related quality of life, work productivity
and health care utilisation. It is also a major cause of
workplace absenteeism [4]. An estimated 158 million
pounds are spent annually on the management of this
condition in the health service [5]. In primary care, the
annual prevalence is 38/1000 in women aged 15–73, a
rate comparable to that of asthma (37/1000) and chronic
back pain (41/1000)[6].
An initial troublesome problem in addressing research
issues related to pelvic pain is the difficulty in making a
definite diagnosis. The following definition is commonly
used and will be adopted for our research proposal: Con-
stant or intermittent, cyclic or acyclic pain, that persists for
6 months or more and includes dysmenorrhoea, deep
dyspareunia and intermenstrual pain [7].
An effective treatment for pelvic pain has evaded gynae-
cologists for centuries. Even today only 20–25% patients
respond to conservative management [8]. When such
treatment fails, a diagnostic laparoscopy is usually per-
formed [2,3,9]. Chronic pelvic pain accounts for up to
40–60% of all diagnostic laparoscopies [2]. The cause of
the pain is not always obvious as no pathology is seen in
40–60% of the cases. When definite pathology is found
the likely causes are endometriosis (25%) and adhesions
(25%) [2]. There is evidence that negative findings at
laparoscopy and follow up with ultrasound will provide
reassurance and relief to some patients. For patients with-
out obvious pathology there is no established treatment.
In recent years, operative laparoscopy has developed rap-
idly and now makes laparoscopic pelvic denervation a
practicable option in the management of chronic pelvic
pain. The nerve plexuses and parasympathetic ganglia in
the uterosacral ligaments, first described in the last cen-
tury [10], and subsequently confirmed [11,12], carry
"pain" from the uterus, cervix and other pelvic structures.
The surgical approach to the management of pelvic pain
is based on interruption of these nerve trunks that can be
achieved by transection of uterosacral ligaments.
The transection of the uterosacral ligaments and the nerve
plexuses it contains is the simplest of the surgical proce-
dures for pelvic pain. The original work by Doyle
described vaginal and abdominal approaches to divide
the attachments of the uterosacral ligaments to the cervix
[13,14]. With the wider use of minimal access therapy
there is a renewed interest in the division of the Franken-
hauser nerve plexus in the uterosacral ligaments laparo-
scopically using lasers or electro-diathermy. In an attempt
to relieve patients' symptoms clinicians frequently per-
form laparoscopic uterosacral nerve ablation, or LUNA as
it is sometimes called. However the efficacy of this proce-
dure has not been assessed objectively using methodolog-
ically sound research.
The Need for the LUNA Trial
Health technology assessment in surgical interventions
requires an initial evaluation of the safety and stability of
new interventions followed by randomised trials [15]. The
initial evaluative evidence alone is not sufficient to assess
the clinical effectiveness of LUNA for which randomised
research remains the gold standard.
Evidence from the medical literature: In the past, pelvic
denervation has been proposed for treatment of chronic
pelvic pain [13] but it has not been widely adopted due to
the need for open invasive surgery. However, recent devel-
opments in minimal access surgery make LUNA a practi-
cable treatment option. Our systematic review [16] has
shown that the currently available research evidence on
LUNA is inconclusive. Therefore further research is
required to generate effectiveness evidence in the form of
a high quality randomised controlled trial. This need is
also supported by the recent Cochrane Reviews [17,18]
that recommend rigorous research to assess surgical inter-
ventions in chronic pelvic pain.
Professional consensus
We conducted a survey of UK gynaecologists associated
with the British Society of Gynaecological Endoscopy in
1998 to determine the extent to which LUNA was being
used in practice [19]. Our survey indicated that despite the
lack of definitive evidence, many gynaecologists familiar
with the technique were using LUNA as a therapeutic
option. Of the 247 respondents, 108 (44%) offered LUNA
to patients: 78% for chronic pelvic pain, 66% endometri-
osis and 18% for dyspareunia/other reasons. Crucially,
this survey indicated that 93 of 108 (86%) gynaecologists
currently performing LUNA were willing to recruit
patients in a randomised trial of LUNA. In this situation
equipoise applies (i.e. the technique has been introduced
without definite evidence but opinion regarding its use is
not yet solidified) making the need for a trial even more
urgent.
Pilot study
We have undertaken a pilot of the LUNA trial with the
objective of assessing its feasibility. It has shown accepta-
bility to patients. It has also established trial management
procedures, piloted questionnaires, measured compliance
and standardised operating procedures. A confidentialBMC Women's Health 2003, 3 http://www.biomedcentral.com/1472-6874/3/6
Page 3 of 10
(page number not for citation purposes)
interim analysis was recently reviewed by an independent
data monitoring committee when the first 60 patients had
completed 6 months follow-up. The committee recom-
mend that a larger study is needed for adequate statistical
power in the trial to evaluate LUNA reliably.
Research Proposal
Objectives
1. To test the hypothesis that in women with chronic pel-
vic pain in whom diagnostic laparoscopy reveals either no
pathology or mild endometriosis (AFS score ≤ 5) LUNA
alleviates pain and improves life quality at 12 months
(principal objective).
2. To test the hypothesis that response to LUNA differs
according to the site and cause of the pain by two second-
ary analyses: (i) Women with central pain, (ii) women
with no visible pathology.
3. To explore the variation in LUNA's effectiveness and
side effects at different periods of follow-up (3, 6, months
and 1, 2, 3, 5 and 10 years).
Design and setting
A multi-centre, prospective, randomised-controlled-trial
involving centres in the UK and elsewhere will be carried
out with single blind assessment of outcomes in eligible
consenting patients randomised at diagnostic laparoscopy
to LUNA (experimental group) or to no pelvic denerva-
tion (control group). Postal questionnaires including vis-
ual analogue scale for pain (primary outcome), an index
of sexual satisfaction and the EuroQol 5D-EQ instrument
(secondary outcomes) will be administered at 3, 6 and 12
months. The primary assessment of the effectiveness of
LUNA will be from comparison of outcomes at the one-
year follow-up, although the medium-term and long-term
risks and benefits of LUNA will also be evaluated postal
questionnaires to the women at 2, 3, 5 and 10 years after
laparoscopy.
Eligibility
All new patients presenting to the Gynaecology outpatient
clinic with pelvic pain (cyclical or noncyclical) and/or
dyspareunia, and requiring diagnostic laparoscopy for
evaluation of these conditions, will be invited to partici-
pate (Protocol, patient information leaflet and the rele-
vant forms and questionnaire available on the LUNA trial
website)[20]. They will be provided with information
leaflet-Appendix A1 [see Additional file 1]. When they
consent to participate (for consent form see Appendix A2-
additional file 1), they are registered prior to randomisa-
tion (Appendix B- additional file 1) and an On study form
is filled (Appendix C-see additional file 1)
Inclusion criteria
• Pelvic pain of longer than 6-month duration.
• Pain located within the true pelvis or between and
below the anterior iliac crests.
• Associated functional disability.
• Lack of response to medical treatment.
• Diagnostic laparoscopy planned.
Exclusion criteria
• Previous LUNA.
• Mild, moderate and severe endometriosis (American
Fertility Society score >5).
• Previous surgery for endometriosis.
• Previous surgery for pelvic inflammatory disease.
• Previous hysterectomy.
• Adnaexal pathology.
Interventions
Diagnostic laparoscopy plus uterosacral nerve ablation
(experimental group) or laparoscopy without pelvic den-
ervation (control group).
Laparoscopic uterosacral nerve ablation will be carried
out in a uniform manner by named surgeons in each of
the participating centres following a common protocol as
described in the standard surgical text [21]. Routine prep-
aration will be made for a diagnostic laparoscopy with the
patient under general anaesthesia. Following pneumoper-
itoneum, a laparoscope will be used to visualise the pelvis.
Before embarking on operative laparoscopy an anatomi-
cal pelvic assessment will be performed to identify pelvic
structures and pathology. At this stage patients with
pathology outlined in the exclusion criteria will be
excluded. It is expected that around 30% of women will
be unsuitable for LUNA at operation and will be 'regis-
tered only' cases. Eligible patients will be randomised by
a telephone call to the Birmingham University Clinical
Trials Unit.
Clear identification of the uterosacral ligaments is a pre-
requisite to treatment with lasers or electro-diathermy.
The posterior leaf of the broad ligament will be carefully
inspected to identify the course of the ureters, which on
rare occasions could be particularly close to the uterosac-
ral ligaments. Care will also be taken to note thin walled
pelvic veins, which often lie lateral to the uterosacralBMC Women's Health 2003, 3 http://www.biomedcentral.com/1472-6874/3/6
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ligaments. If accidentally punctured, they may cause trou-
blesome bleeding requiring further endoscopic endocoag-
ulation. The uterosacral ligaments will be identified by
manipulation of the uterus in the right and left lateral
planes. The ligaments will then be ablated with laser or
micropoint electro-diathermy or endocoagulation
depending upon the surgeons' preference. The ablation
will start as close to the posterior aspect of the cervix as
possible and continue for a minimum of 1 cm posterola-
terally on either side. The aim of the procedure is to
destroy the sensory nerve fibres and the secondary ganglia
as they leave the uterus and come to lie within the utero-
sacral ligaments.
The safe conduct of operative laparoscopy for LUNA
requires the use of two ports, one for delivery of the energy
source (laser or diathermy) and another for manipula-
tion. These are in addition to the umbilical port used for
the laparoscope itself. In contrast, diagnostic laparoscopy
in women with no pathology requires only one port in
addition to the umbilical laparoscopic port. This differ-
ence in number of ports has potential for introducing bias
by compromising patient blinding to group allocation. A
sham incision (see Blinding and Ethical Considerations)
in the control group is used to overcome this problem.
Randomisation
Consenting eligible patients will be randomised to diag-
nostic laparoscopy plus uterosacral nerve ablation (exper-
imental group) or to no pelvic denervation at the time of
diagnostic laparoscopy (control group). Important issues
related to randomisation are considered below:
Allocation Sequence
The subjects will be allocated to groups using a chance
procedure, blocking and stratification [22]. Stratified
block randomisation will be employed to ensure that
there will be nearly equal numbers of patients in the two
groups within the prognostic subgroups, even if the study
ends prematurely. Variable block size will be used to
avoid any possibility of foreknowledge. Stratified alloca-
tion is used so that chance imbalances in the stratification
variable do not have an effect on the outcome. Since
response to treatment may depend on the surgeons' tech-
nique for laparoscopic uterosacral nerve ablation, analy-
ses will be retrospectively stratified according to the
surgeons participating in the trial.
Intraoperative randomisation
Allocation concealment is a crucial factor in avoiding bias
in randomised trials [23]. Although it is not possible to
blind the surgeon, it is essential to keep the surgeon blind
to the group allocation until after the irrevocable decision
to enter the woman into the trial has been made. So, in
LUNA, treatment allocation will be issued at diagnostic
laparoscopy, after the surgeon has inspected the pelvis
and ensured that the patient fulfils all of the inclusion cri-
teria and she does not have any of the exclusion criteria.
Women may be randomised or registered into the study
by telephoning the toll free Randomisation Line on 0800
953 0274 (+44 121 687 2319 from outside the UK) or by
Internet randomisation at http://www.luna.bham.ac.uk
and clicking on the randomisation button. Passwords for
Internet randomisation will only be allocated to centres
with ethical approval.
Following surgery, the surgeon fills in operation details on
a post-surgery form (Appendix D- see additional file 1)
Blinding
In the LUNA study, patients will be kept blind to their
treatment allocation until the follow-up in the trial is
complete. Patients may also show a placebo effect if they
know they have received the active treatment. The magni-
tude of placebo effects should not be underestimated.
There is clear evidence that inadequacies of blinding in
randomisation lead to exaggeration of treatment effect in
randomised trials [24].
However, there is a potential problem in the maintenance
of blinding in the LUNA trial. As mentioned earlier,
patients allocated to have LUNA will have the standard
operative laparoscopy with three ports (one 10 mm
umbilical port and two 5 mm lateral ports), whereas
patients allocated to the control group under normal cir-
cumstances would have standard diagnostic laparoscopy
with two ports (one 10 mm umbilical port and one 5 mm
lateral or midline port). By noting the different number of
incisions some patients might become aware of their
group allocation and this might alter their response. In
order to maintain patient blinding, a sham 5 mm skin
incision is made superficially in a lateral port site. This
approach in avoiding bias due to lack of blinding has
been used in a previous trial of laparoscopic nerve abla-
tion [25] and has also received ethical approval in this
trial.
A second purpose of blinding is to prevent differences in
other aspects of patient management introducing biases
affecting the results. The patient's GP will therefore be
kept blind to treatment allocation. Double blinding is not
possible in LUNA, however, as the surgeons performing
the surgical intervention on the patients will be aware of
the group allocation. However, the likelihood that this
will lead to bias in outcome assessment is low as the
patient outcome assessments in this study will be con-
ducted by self-administered questionnaires, avoiding any
possible bias from surgeons' knowledge of group
allocation.BMC Women's Health 2003, 3 http://www.biomedcentral.com/1472-6874/3/6
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Endpoints
Primary Outcome measure: Visual analogue scale for 
assessment of pain
Pain is difficult to measure, partly because it is accompa-
nied by other sensations and partly because the reaction
component affects the judgement of the pain regardless of
the intensity of the stimulus. A measure of pain is never-
theless essential to the outcome of this clinical trial. Visual
analogue scales (VAS) originally devised as measures of
well being,[26] have been successfully adapted to measure
pain [27,28]. This technique involves use of a 10 cm line
on a piece of paper representing a continuum of the
patients' opinion of the degree of pain. It is explained to
the patient that the one extreme of the line represents "no
pain at all" while the other represents "as much pain as
she can possibly imagine". The subject rates the degree of
pain by placing a mark on the line and scale values are
obtained by measuring the distance from zero to that
mark. Visual analogue scales (VAS) in the assessment of
pain have been established to be reproducible and accu-
rate [28]. VAS has commonly been used in measurement
of chronic pain [29]. All the studies of LUNA included in
systematic reviews so far have used this measure, or a var-
iation on it, for assessing outcome. Individual pain scores
have sufficient psychometric strengths to be used in
chronic pain research involving group comparison
designs[30].
Secondary Outcome measures
Assessment of sexual function
Sexual function is an important aspect of life quality in
patients with pelvic pain. Pain itself is an anti-aphrodisiac,
and together with discomfort and altered self image, it
impacts upon sexual function [31]. Its assessment in an
objective manner is therefore an important part of the
LUNA trial. There are several sexual function instruments,
with high levels of reliability, validity and responsiveness,
which yield comparable results across occasions and indi-
viduals, making them suitable for monitoring therapeutic
progress in randomised research [31].
The Sexual Activity Questionnaire (SAQ)[32] will replace
the Brief Index of Sexual Satisfaction (ISS) [33] for the
assessment sexual function. The outcome measure has
been changed because of poor acceptability and compli-
ance with the ISS. The SAQ has excellent internal consist-
ency and test retest reliability. It also has excellent
concurrent and construct validity and has been shown to
be acceptable to women in other clinical trials [34] In the
questionnaire it will be clearly stated that the measure of
sexual function covers material that is sensitive and per-
sonal. Participants will be reassured that their responses
will be kept completely confidential and that if they do
not wish to answer any questions, they will be allowed to
leave the questionnaire blank.
Health-related quality of life Instrument
Health-related quality of life (HRQL) instruments are
becoming powerful tools for outcome assessments in ran-
domised trials. Quality of life instruments assess aspects
of patient's health status usually not grasped by conven-
tional clinical indices; hence, they can be applied as com-
plementary assessments together with VAS and ISS.
Quality of life has to be defined clearly and patient's per-
ception of normal performance serves a pivotal role in this
context. HRQL instruments are administered with ques-
tionnaires assessing a number of different domains, i.e.
areas of behaviour or experience that the instrument is
attempting to measure [35].
Resource usage outcome measures
LUNA is a quick, safe and inexpensive procedure for
women already undergoing diagnostic laparoscopy. Our
hypothesis is about a clinically important effect without
an excess of complications. If the hypothesis is confirmed,
then any benefits will essentially be "dominant" out-
weighing the relatively small costs of intervention. There-
fore, we do not plan a formal economic evaluation at this
stage. However, data on health resource use will be col-
lected partly as efficacy outcome measures (i.e. less need
for medical care for pelvic pain indicates greater efficacy),
and partly to allow an economic evaluation to be carried
out, should significant complications occur. Other meas-
ures will include analgesic use, consultations at general
practice and hospital, and time off work. Again these are
both economic outcomes and indicators of residual pain.
Follow-up
Postal Questionnaires to assess pain and sexual function
will be administered at enrolment in the trial and then at
3, 6, 12, 24 and 36 months after laparoscopy. The out-
comes at 12 months will be used to address the primary
research question. This time interval is chosen because
laparoscopy alone has a placebo effect for up to 3–6
months in some patients [36,37]. The 24 and 36-month
follow up will be used to monitor medium-term effects of
the intervention. Existing participants in the trial who
consented to 3 years of follow-up will be asked to consent
to long-term follow-up (10 years) once they have reached
the 3 year follow up time-point. Participants randomised
after June 2003 are asked to consent to 10 years of follow-
up at entry for long term follow up.
Ineligible Patients – follow-up only
Women who are ineligible for the LUNA trial because of
moderate to severe endometriosis, significant adhesions,
significant pelvic inflammatory disease, other significant
pathology or those for whom LUNA is not technically fea-
sible should be registered with the Trial Office for follow-
up only. The woman should be told that she was not eli-
gible for the trial randomisation, and the reasons why,BMC Women's Health 2003, 3 http://www.biomedcentral.com/1472-6874/3/6
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and asked if she would agree to complete the follow-up
questionnaires at 6 and 12 months.
This non-random cohort will provide comparative data
on the natural history of patients with chronic pelvic pain
with significant pathology.
Side-effects quantification
The centres have been advised to fill an " adverse event
form" in case of immediate and delayed complications if
any are associated with the procedure.
Sample Size and Power Considerations
The sample size for this trial has been estimated using the
hypothesis that LUNA will alleviate pain symptoms (i.e.
reduce pain scores on a VAS) more often than no interven-
tion at one-year following diagnostic laparoscopy. Cohen
describes 'effect sizes' of 0.2 and 0.5 standard deviations
(SD) as 'small' and 'medium' [38]. Interim analyses of the
pilot study indicate that the SD of the difference in change
in VAS scales between LUNA and no pelvic denervation
groups will be about 4.0. This corresponds to small and
medium effect sizes on VAS of 0.8 and 2.0 respectively
and is consistent with other studies of chronic pelvic pain,
where clinically important symptom alleviation has been
defined as a reduction in pain score of 2 or more [39]. To
confirm or refute a small to medium effect of LUNA (0.3
SD difference), based on ά = 0.05 and β = 0.2 (80%
power), 175 patients in each group (i.e. 350 patients in
total) will be required. Considering a 20% loss to follow-
up, the sample size is inflated to 210 patients in each
group (i.e. 420 patients in total).
Stratification Variables
Randomisation will be conducted using minimisation,
stratified by the four variables:
a. Presence or absence of some minimal pathology (min-
imal endometriosis ± ablation; adhesions requiring adhe-
siolysis only; minimal pelvic inflammatory disease)
b. Site of pain (presence of central pain or not)
c. Parity of the woman (nulliparous or parous)
d. Whether the woman is sexually active or not
The first two variables form the prespecified subgroup
analyses, and the other two variables are included as hav-
ing impact on dysmenorrhoea and dyspareunia
respectively.
Data Analysis
Type of analysis
Intention to treat
The main analysis to address the principal research ques-
tions will be conducted using the one-year follow-up data.
The mean differences in VAS pain scores; sexual satisfac-
tion and life quality scores in the two groups will be com-
pared using a two-sample t-test. The rates of women with
clinically significant (2 VAS point) alleviation of pain
symptoms will also be compared producing a relative risk
estimate with 95% confidence intervals (Mantel-Haenzel
test). Baseline characteristics of the patients enrolled in
the two groups will be compared to ensure that randomi-
sation has produced comparable groups of patients. The
use of additional treatment (co-intervention) for pelvic
pain following LUNA or no pelvic denervation will be
assessed for any systematic difference between the two
groups.
Subgroup analyses are limited by statistical power and can
produce spurious results particularly if many are under-
taken. Our literature review [16] and consultation with
gynaecologists [19] suggests that the effectiveness of
LUNA may be greater for central compared to non-central
pain and if there is no associated pathology (i.e. no
endometriosis). Therefore, we have chosen to limit sec-
ondary analyses to these subgroups only. The LUNA trial
is powered to detect a small to medium overall difference
and if a larger treatment benefit is found then other sub-
group analyses will be undertaken, appropriately cau-
tiously. The LUNA trial is powered overall at 80% to
detect a 0.3 SD difference in effect. Our pilot study shows
that 60% patients have mainly central pain and 70% have
no pathology. Hence, in the subgroup with central pain
the power will be 80% to detect a 0.4 SD treatment effect.
In the subgroup with no pathology the power will be 80%
to detect a 0.35 SD treatment effect.
Frequency of analyses
Interim analysis at completion of 6 months follow-up of
the first 60 patients has already been completed as pilot
study.
Bi-annual analyses of recruitment, compliance and loss to
follow-up are being carried out for LUNA Trial Manage-
ment Committee.
An annual interim analysis of effectiveness is done for
confidential review by independent Data Monitoring
Committee to determine whether the principal question
has been answered and to monitor adverse events.
Main analyses of effectiveness of LUNA will be done at
completion of one year follow up of the total study sam-
ple. Additional analysis of long-term effects will be done
at two and three-year follow-up points.BMC Women's Health 2003, 3 http://www.biomedcentral.com/1472-6874/3/6
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Ethical considerations
When there is uncertainty about the appropriate therapy,
scientific clinical trials are the best scientifically ethical
way to resolve uncertainty and thereby benefit both the
individual patients and all others concerned in their care
[40]. The need for a "sham" incision in this trial is the
main ethical issue and it is required because without it the
patients cannot be kept blinded. The purpose of blinding
is to prevent various biases from affecting the results. The
need for blinding in surgical trials has been emphasised in
the medical literature [41] and there is empirical evidence
that inadequacies of blinding in randomisation lead to
exaggeration of therapeutic efficacy in randomised trials
[42]. Blinding of patients in surgical trials is clearly indi-
cated when the intervention primarily treats symptoms
and when the outcomes are based on patients' own assess-
ment. LUNA is an intervention for treating chronic pelvic
pain (a diagnosis based on symptoms) and the outcome
assessment is based on patients' responses on a visual ana-
logue pain scale and a quality of life instruments. Hence,
the use of a "sham" incision is justified if bias is to be
avoided in the LUNA trial and this approach has been
used in a previous trial of LUNA [43]. Ethical approval for
the LUNA trial procedures has already been obtained
from the Multicentre Research Ethics Committee (MREC).
Conduct of the Study and Data Management
The trial will be managed from the Birmingham Clinical
Trials Unit. Each investigating centre will carry out the
study in accordance with the study protocol and to the
MRC guidelines on Good Clinical Practice in Clinical
Research (1998). Patients will be invited to participate if
they fulfil all the inclusion criteria and do not have any
exclusion criteria (See Appendix B Eligibility Checklist
and Randomisation Form). They will be provided with a
laparoscopy and LUNA trial information leaflet (Appen-
Pelvic sensory nerve pathways and site for luna Figure 1
Pelvic sensory nerve pathways and site for lunaBMC Women's Health 2003, 3 http://www.biomedcentral.com/1472-6874/3/6
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dix A1) and signed consent obtained prior to laparoscopy
(Appendix A2). Consenting patients should be asked to
complete the Enrolment Questionnaire and On Study
Form. The final decision to enrol patient in the trial will
depend on the findings at laparoscopy when the surgeon
will perform LUNA or not after determining eligibility as
shown in Eligibility Checklist and Randomisation Form
(see Appendix B). At the end of the procedure the surgeon
will complete the Post Surgery Form (Appendix D). All the
three forms for each patient enrolled will be photocopied
to keep a record at the participating centre and the origi-
nals will be sent to the Birmingham Clinical Trials Unit,
which will act as the co-ordinating centre. At 3, 6 and 12
months after enrolment, the Follow-up Questionnaire
will be mailed to the patients with a pre-paid self-
addressed envelope. Recruitment is expected to take 12
months and follow up for the main endpoints another 12
months. At completion of the main study further Follow-
up questionnaires will be mailed out at 24 and 36
months.
Finishing date
September 2005; expected reporting date: December 2006
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mingham, UK); S Irani (Birmingham Heartlands and
Solihull Hospital NHS Trust, UK); KSK, PL, JKG, C Mann,
TJ Clarke (Birmingham Women's Hospital, Birmingham,
UK); V Kay (Forth Park Hospital, Kirkcaldy, UK); D Phil-
lips (Perth Royal Infirmary, UK); JS Samra, C Cox (New
Table 1: Study Flow Chart
Clinic Theatre Follow up (months/ years)
36 1 2 235 1 0
Patient information and consent (App A) x
Eligibility Checklist and Randomisation form (App B) x x
Enrolment Questionnaire (Appendix C1) x
Surgery Form (Appendix D) x
Letter to GP (Appendix E) x
F o l l o w - u p  Q u e s t i o n n a i r e  ( A p p e n d i x  C 2 ,  C 3 ) xxxxxxxBMC Women's Health 2003, 3 http://www.biomedcentral.com/1472-6874/3/6
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Cross Hospital, Wolverhampton, UK); S Keay (Walsgrave
Hospital, Coventry, UK); E Shaxted (Northampton Gen-
eral Hospital, UK) and J Thornton (City Hospital, Not-
tingham, UK) The following centres have obtained ethics
approval and await recruitment: A Ali (Darlington Memo-
rial Hospital, UK); C Chandler (Billinge Hospital, Wigan,
UK); E Downes (Chasefarm Hospital, Enfield, UK); A
Hextall (St Albans City Hospital, UK);J Kabukoba (Sand-
well Hospital, West Bromwich, UK); M Katesmark
(Epsom General Hospital, UK); P. Kirwan (Leicester Gen-
eral Hospital, UK); K Louden (Royal Hampshire Hospital,
UK);J Moohan (Altnagelvin Area Hospital, UK); S Najja
(Queen's Park Hospital, Blackburn, UK); K Olah (War-
wickshire General Hospital, UK); M Padwick (Watford
General Hospital, UK); P Owen (Stobhill Hospital, Glas-
gow, UK) and A Tapp (Royal Shrewsbury Hospital, UK).
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